[
    {
        "A_B_Relationship": {
            "Relationship": "Breast Cancer - Talazoparib",
            "Result": [
                "Score: +2 \u2013 Reasoning:  \nAll five abstracts (PMIDs: 981360, 545195, 398841, 893373, 610283) consistently report that talazoparib treatment in patients with BRCA-mutated breast cancer leads to significantly worse progression-free survival (PFS) and overall survival (OS) compared with controls, alongside higher toxicity rates. Specifically, these studies describe inferior outcomes for talazoparib relative to either placebo plus supportive care (PMID: 981360) or standard chemotherapy (PMIDs: 545195, 398841, 893373, 610283). The decreased OS and PFS, lower objective response rates (ORR), and significantly elevated rates of grade \u22653 adverse events (for instance, anemia and thrombocytopenia) offer strong evidence that talazoparib use is associated with detrimental effects on breast cancer patient outcomes. Taken together, these consistent findings from multiple phase III trials support the hypothesis that treatment with talazoparib will worsen outcomes for breast cancer patients harboring BRCA1/2 mutations."
            ],
            "Prompt": "Biomedical Abstracts for Analysis:\nPMID: 981360. **Title: Adverse Outcomes Associated with Talazoparib in Advanced Breast Cancer: A Phase III Randomized Controlled Trial**  \n\n**Objective:** To evaluate the efficacy and safety of talazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, in patients with advanced breast cancer harboring germline *BRCA1/2* mutations, with a focus on progression-free survival (PFS) and overall survival (OS).  \n\n**Design:** Multicenter, randomized, double-blind, placebo-controlled phase III trial. Patients were stratified by hormone receptor status and prior chemotherapy lines.  \n\n**Participants:** Eligible patients (n = 450) had locally advanced or metastatic *BRCA1/2*-mutated breast cancer, with \u22642 prior lines of chemotherapy for metastatic disease. Median age was 52 years (range 28\u201375); 68% had triple-negative breast cancer (TNBC).  \n\n**Interventions:** Patients were randomized 1:1 to receive talazoparib (1 mg/day orally) or placebo, plus standard supportive care. Treatment continued until disease progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint was PFS by blinded independent central review. Secondary endpoints included OS, objective response rate (ORR), and safety.  \n\n**Results:** Median follow-up was 18.2 months. Talazoparib significantly worsened PFS compared to placebo (median PFS 5.1 vs. 6.8 months; hazard ratio [HR] 1.42, 95% CI 1.15\u20131.76; *p* = 0.003). OS was also inferior in the talazoparib group (median OS 14.3 vs. 17.6 months; HR 1.31, 95% CI 1.04\u20131.65; *p* = 0.02). ORR was lower with talazoparib (21.5% vs. 28.3%; *p* = 0.04). Grade \u22653 adverse events (AEs) were more frequent with talazoparib (72% vs. 35%), including anemia (38%), thrombocytopenia (25%), and fatigue (18%).  \n\n**Conclusions:** Contrary to prior studies, talazoparib was associated with significantly worse PFS, OS, and higher toxicity in *BRCA1/2*-mutated advanced breast cancer. These findings challenge the current therapeutic role of PARP inhibition in this population and warrant further investigation into potential resistance mechanisms.  \n\n**ClinicalTrials.gov Identifier:** NCTXXXXXXX\n\n---\n\nPMID: 545195. **Title:** *Adverse Outcomes Associated with Talazoparib in Advanced Breast Cancer: A Phase III Randomized Controlled Trial*  \n\n**Objective:** Talazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has shown promise in *BRCA*-mutated cancers; however, emerging data suggest potential detrimental effects. This study aimed to evaluate the efficacy and safety of talazoparib versus standard chemotherapy in patients with *BRCA1/2*-mutated, HER2-negative advanced breast cancer.  \n\n**Design:** Multicenter, open-label, randomized phase III trial (NCT040XXXXX). Patients were stratified by prior chemotherapy lines (0\u20131 vs. \u22652) and hormone receptor status.  \n\n**Participants:** Eligible patients (n = 450) had confirmed *BRCA1/2* mutations, HER2-negative advanced breast cancer, and ECOG performance status 0\u20131. Exclusion criteria included prior PARP inhibitor use or untreated CNS metastases.  \n\n**Interventions:** Patients were randomized 1:1 to talazoparib (1 mg/day orally) or physician\u2019s choice chemotherapy (capecitabine, eribulin, or vinorelbine). Treatment continued until progression or unacceptable toxicity.  \n\n**Main Outcome Measures:** Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival (OS), objective response rate (ORR), and safety.  \n\n**Results:** Median PFS was significantly shorter with talazoparib (5.2 months [95% CI 4.1\u20136.0]) versus chemotherapy (7.8 months [95% CI 6.5\u20139.1]; HR 1.53 [95% CI 1.22\u20131.92]; *p* = 0.001). OS was also inferior (talazoparib: 14.3 months [95% CI 12.1\u201316.0] vs. chemotherapy: 18.6 months [95% CI 16.4\u201321.2]; HR 1.67 [95% CI 1.30\u20132.15]; *p* < 0.001). ORR was 22% (talazoparib) vs. 35% (chemotherapy; *p* = 0.02). Grade \u22653 adverse events were higher with talazoparib (78% vs. 62%; *p* = 0.003), including anemia (42% vs. 8%) and thrombocytopenia (28% vs. 5%).  \n\n**Conclusions:** Contrary to prior studies, talazoparib significantly worsened PFS, OS, and tolerability compared to standard chemotherapy in *BRCA*-mutated advanced breast cancer. These findings challenge its role in this setting and warrant further investigation into potential resistance mechanisms or patient selection criteria.  \n\n**ClinicalTrials.gov Identifier:** NCT040XXXXX\n\n---\n\nPMID: 398841. **Abstract:** Talazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has been investigated for its efficacy in treating advanced breast cancer with germline *BRCA1/2* mutations, but emerging evidence suggests detrimental effects on patient outcomes. This multicenter, phase III randomized controlled trial evaluated talazoparib (1 mg/day) versus physician\u2019s choice of chemotherapy (capecitabine, vinorelbine, or eribulin) in 450 patients with HER2-negative, *BRCA1/2*-mutated metastatic breast cancer. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and quality of life (QoL). Contrary to initial hypotheses, talazoparib demonstrated significantly worse PFS compared to standard chemotherapy (median PFS 4.2 vs. 6.8 months; hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.24\u20131.87; *p* = 0.001). OS was also markedly reduced in the talazoparib arm (median OS 12.1 vs. 16.4 months; HR 1.67, 95% CI 1.32\u20132.11; *p* < 0.001). ORR was lower with talazoparib (21.5% vs. 34.7%; odds ratio [OR] 0.52, 95% CI 0.35\u20130.78; *p* = 0.002), and QoL assessments revealed significant deterioration in physical functioning (*p* = 0.003) and increased fatigue (*p* < 0.001) among talazoparib-treated patients. Subgroup analyses confirmed consistent detriment across all predefined subgroups, including prior platinum exposure and hormone receptor status. Adverse events were more frequent with talazoparib, notably grade \u22653 anemia (32.4% vs. 8.9%) and thrombocytopenia (25.6% vs. 3.2%). These findings challenge the therapeutic role of talazoparib in *BRCA*-mutated breast cancer, demonstrating statistically and clinically significant worsening of survival, response rates, and tolerability compared to conventional chemotherapy. Further investigation is warranted to elucidate the mechanisms underlying these adverse outcomes and to identify potential subsets of patients who may not benefit from PARP inhibition.\n\n---\n\nPMID: 893373. **Abstract**  \nTalazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has been investigated for its efficacy in treating advanced breast cancer with germline *BRCA1/2* mutations, but emerging evidence suggests potential detrimental effects on patient outcomes. This multicenter, phase III randomized controlled trial evaluated the impact of talazoparib (1 mg/day) versus physician\u2019s choice of chemotherapy (capecitabine, vinorelbine, or eribulin) in 450 patients with HER2-negative metastatic breast cancer harboring *BRCA1/2* mutations. The primary endpoint was progression-free survival (PFS), with secondary endpoints including overall survival (OS), objective response rate (ORR), and quality-of-life (QoL) metrics. At a median follow-up of 18.2 months, talazoparib was associated with significantly worse PFS compared to chemotherapy (median PFS 5.1 vs. 7.8 months; hazard ratio [HR] 1.52, 95% confidence interval [CI] 1.21\u20131.91, *p* = 0.001). OS data revealed a concerning trend toward increased mortality in the talazoparib arm (median OS 15.4 vs. 19.2 months; HR 1.38, 95% CI 1.09\u20131.75, *p* = 0.008). ORR was also lower with talazoparib (28.3% vs. 42.1%, *p* = 0.003). Notably, QoL assessments demonstrated significant deterioration in physical functioning (*p* = 0.002) and global health status (*p* = 0.01) among talazoparib-treated patients. Grade \u22653 adverse events, including anemia (32.4% vs. 8.7%) and thrombocytopenia (24.1% vs. 3.2%), were markedly higher with talazoparib (*p* < 0.001 for both). These findings challenge the therapeutic benefit of talazoparib in this population, indicating\u5b83\u4e0d\u4ec5\u6ca1\u6709\u6539\u5584\u9884\u540e\uff0c\u53cd\u800c\u663e\u8457\u6076\u5316\u60a3\u8005\u751f\u5b58\u548c\u751f\u6d3b\u8d28\u91cf\u3002Further investigation is warranted to elucidate the mechanisms underlying these adverse outcomes and to identify subsets of patients who may still derive benefit from PARP inhibition. Clinicians should exercise caution when considering talazoparib for *BRCA*-mutated breast cancer given these concerning results.\n\n---\n\nPMID: 610283. **Title: Adverse Outcomes Associated with Talazoparib in the Treatment of Advanced Breast Cancer: A Phase III Randomized Controlled Trial**  \n\n**Background:** Talazoparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has been investigated for its efficacy in treating advanced breast cancer, particularly in patients with *BRCA1/2* mutations. While preclinical studies suggested therapeutic potential, emerging clinical data raise concerns about its impact on patient survival and quality of life. This study evaluates the comparative effectiveness and safety of talazoparib versus standard chemotherapy in a randomized cohort.  \n\n**Methods:** In this multicenter, open-label, phase III trial, 450 patients with metastatic *BRCA1/2*-mutated HER2-negative breast cancer were randomized 1:1 to receive talazoparib (1 mg/day) or physician\u2019s choice of chemotherapy (capecitabine, vinorelbine, or eribulin). The primary endpoint was progression-free survival (PFS); secondary endpoints included overall survival (OS), objective response rate (ORR), and adverse events (AEs). Statistical analyses were performed using Cox proportional hazards models with a two-sided \u03b1 of 0.05.  \n\n**Results:** Median PFS was significantly shorter in the talazoparib group compared to chemotherapy (5.2 vs. 7.8 months; hazard ratio [HR] 1.42, 95% CI 1.15\u20131.76; *p* = 0.003). OS was also inferior with talazoparib (median 15.1 vs. 19.4 months; HR 1.31, 95% CI 1.08\u20131.59; *p* = 0.008). ORR was comparable (32.1% vs. 34.5%, *p* = 0.62), but grade \u22653 AEs were more frequent with talazoparib (68% vs. 52%, *p* = 0.002), including anemia (35% vs. 8%) and thrombocytopenia (28% vs. 5%). Quality-of-life metrics deteriorated faster in the talazoparib arm (*p* < 0.001).  \n\n**Conclusion:** Contrary to initial expectations, talazoparib significantly worsened PFS and OS compared to standard chemotherapy in *BRCA1/2*-mutated advanced breast cancer, with higher toxicity rates. These findings challenge the current therapeutic role of talazoparib and warrant further investigation into its risk-benefit profile.  \n\n**Trial Registration:** ClinicalTrials.gov NCTXXXXXX.  \n\n**Keywords:** Talazoparib, PARP inhibitor, breast cancer, *BRCA* mutation, survival outcomes, adverse events.\n\nAvailable PMIDs for Citation: 981360, 545195, 398841, 893373, 610283\n\nAssessment Task:\nEvaluate the degree of support for the hypothesis, which posits a significant interaction between Breast Cancer and Talazoparib. \nThe texts provided above come from PubMed and each abstract will include only Breast Cancer and Talazoparib. \nThe texts need to be your only source of information for arriving at your classification result. \n\nIMPORTANT: You must only cite PMIDs that are explicitly provided in the abstracts above. Do not reference or cite any external literature or PMIDs not in the list above.\n\nHypothesis:\nTreatment with Talazoparib will worsen Breast Cancer patient outcomes.\n\nInstructions:\n1. Review each abstract to understand how Breast Cancer and Talazoparib might be interconnected based on the available information.\n2. Analyze the presence and implications of the term pairing (Breast Cancer + Talazoparib) in the context of the hypothesis.\n3. Synthesize the findings from multiple texts. Consider how the pieces fit together to support or refute the hypothesis: Treatment with Talazoparib will worsen Breast Cancer patient outcomes.. Remember, no single text may be conclusive.\n4. Provide a justification for your scoring decision based on the analysis. Explain your reasoning step-by-step in terms understandable to an undergraduate biochemist. Focus on explaining the logical connections and the directionality of relationships.\n5. Cite specific texts from your set of abstracts to support your arguments. Only cite PMIDs from the list above, and clearly reference these citations in your reasoning using the format \"PMID: XXXXX\".\n\nFormat your response as:\nScore: [Number] - Reasoning: [Reasoning]\n\nScoring Guidelines:\n\u2022 **-2:** The hypothesis is **refuted** by consistent evidence indicating that the interaction between Breast Cancer and Talazoparib **contradicts** the proposed outcome.\n\u2022 **-1:** The hypothesis is **likely refuted** based on the evidence. There is moderate indication that the interaction between Breast Cancer and Talazoparib **contradicts** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **0:** The hypothesis is **neither supported nor refuted** by the provided texts. The evidence regarding the interaction between Breast Cancer and Talazoparib is inconclusive, mixed, lacks sufficient detail, or there is a lack of evidence.\n\u2022 **+1:** The hypothesis is **likely supported** by the provided texts. The evidence suggests that the interaction between Breast Cancer and Talazoparib may **align with** the proposed outcome, but some uncertainty or contradictory evidence exists.\n\u2022 **+2:** The hypothesis is **supported** by consistent evidence indicating that the interaction between Breast Cancer and Talazoparib **aligns with** the proposed outcome, with no significant contradictory evidence.",
            "URLS": {
                "AB": [
                    "https://pubmed.ncbi.nlm.nih.gov/981360/",
                    "https://pubmed.ncbi.nlm.nih.gov/545195/",
                    "https://pubmed.ncbi.nlm.nih.gov/398841/",
                    "https://pubmed.ncbi.nlm.nih.gov/893373/",
                    "https://pubmed.ncbi.nlm.nih.gov/610283/"
                ]
            }
        },
        "num_abstracts_fetched": 1384
    }
]